Éxtasis (3,4-metilendioximetanfetamina, MDMA): aspectos farmacológicos, clínicos y criminológicos

Recio, 1998, Epidemiología del consumo de éxtasis y patrones de uso, 1 Cabrera, 1998 Hardman, 1973, Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals, Toxicol Appl Pharmacol, 25, 299, 10.1016/S0041-008X(73)80016-X Eisner, 1995 Prada, 1996, MDMA o éxtasis: aspectos farmacológicos, toxicológicos y clínicos, Med Clin (Barc), 107, 549 Garrido-Lestache, 1995, Alarma social por el consumo de MDMA (metilendioximetanfetamina) en España, Acta Technol Legis Medicament, 6, 431 Merrill, 1996, Ecstasy and neurodegeneration, Advice is that «less is more» Br Med J, 313, 423, 10.1136/bmj.313.7054.423 Green, 1996, Ecstasy and neurodegeneration, Br Med J, 312, 1493, 10.1136/bmj.312.7045.1493 Saunders, 1996, Ecstasy and neurodegeneration, No evidence of neurotoxicity exists Br Med J, 313 Lyttle, 1992, Drugs, music and ideology: a social pharmacological interpretation of the acid house movement, Int J Addictions, 27, 1159, 10.3109/10826089209047341 Henry, 1992, Toxicity and deaths from 3,4-methylenedioxy-methamphetamine (ecstasy), Lancet, 340, 384, 10.1016/0140-6736(92)91469-O Spruit, 1999, Ecstasy use and policy response in the Netherlands, J Drug Issues, 29, 653, 10.1177/002204269902900312 Webb, 1996, Alcohol and drug use in UK university students, Lancet, 348, 922, 10.1016/S0140-6736(96)03410-1 Landry, 2002, MDMA: a review of epidemiologic data, J Psychoact Drugs, 34, 163, 10.1080/02791072.2002.10399950 1996 Navarro, 1998 Elzo J. Drogas y escuela. Opinión 1996;20(dossier 21). Bobes, 2002, Use of MDMA and other illicit drugs by young adult males in northern Spain: a five-year study, Eurb Addict Res, 8, 147, 10.1159/000059385 2000 2002 Von Sydow, 2002, Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - A transient phenomenon? Results from a longitudinal community study., Drug Alcohol Depend, 66, 147, 10.1016/S0376-8716(01)00195-8 Schuckit, 1994, MDMA (ecstasy): an old grug with new tricks, Drug Abuse Alcohol Newsll, 23, 1 Randall, 1992, Ecstasy-fueled rave parties become dances of death for english youths, Jama, 268, 1505, 10.1001/jama.268.12.1505 Torrens, 1994, La ruta del bakalao, Addiction, 89, 619 Boot, 2000, MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks, Lancet, 355, 1818, 10.1016/S0140-6736(00)02276-5 Villa, 1996, Hacia una definición del perfil psicosocial y psicopatológico de los consumidores de éxtasis, An Psiquiatría(Madrid), 12, 183 Schwartz, 1997, MDMA (éxtasis) y «fiestas con música ácida»: una revisión, Pediatrics (Ed. esp.), 44, 281 Esteban, 1995, Derivados anfetamínicos: ¿éxtasis y algo más?, Farmacéuticos, 31, 11 Fitzgerald, 1989, Stereochemistry of the metabolism of MDMA to MDA, Life Sci, 45, 295, 10.1016/0024-3205(89)90138-0 Hiramatsu, 1991, A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effects on monoamine concentrations in brain dialysates, Eur J Pharmacol, 204, 135, 10.1016/0014-2999(91)90697-O Cho, 1990, Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis, Drug Metab Dispos Biol Fate Chem, 18, 686 Lim, 1988, In vivo and in vitro metabolism of 3,4-methylenedioxy-methamphetamine in the rat: identification of metabolites using an ion trap detector., Chem Res Toxicol, 1, 370, 10.1021/tx00006a008 Tucker, 1994, The demethylenation of methylendioxymet-hamphetamine (ecstasy) by debrisoquine hydroxilase (CYP2D6)., Biochem Pharmacol, 47, 1151, 10.1016/0006-2952(94)90386-7 Helmlin, 1996, Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS., J Anal Toxicol, 20, 432, 10.1093/jat/20.6.432 Camí, 1997, Pharmacokinetics of ecstasy (MDMA) in healthy subjects., Eur J Clin Pharmacol Quinn, 1997, Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users., Clin Pharmacokinet, 33, 344, 10.2165/00003088-199733050-00003 Kumagai, 1994, Participation of cytochrome P450-2B and-2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats., Mol Pharmacol, 45, 359 De la Torre, 1999, Fatal MDMA intoxication, Lancet, 353, 593, 10.1016/S0140-6736(05)75653-1 Topp, 1999, Ecstasy use in Australia: Patterns of use and associated harm, Drug Alcohol Depend, 55, 105, 10.1016/S0376-8716(99)00002-2 Frederick, 1997, Effects of MDMA on complex brain function in laboratory animals, Neurosci Biobehav Rev, 21, 67, 10.1016/0149-7634(95)00064-X Álamo, 1998, neurobiológicos del consumo de éxtasis, 24 Burnat, 1996, L'ecstasy: psychostimulant, hallucinogène et toxique., Presse Med, 25, 1208 Huether, 1997, Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners., J Neural Transm, 104, 771, 10.1007/BF01285547 Schmidt, 1987, In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain., Biochem Pharmacol, 36, 747, 10.1016/0006-2952(87)90729-5 Rothman, 2001, Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin., Synapse, 39, 32, 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 Gudelsky, 1996, Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions., J Neurochemistry, 66, 243, 10.1046/j.1471-4159.1996.66010243.x Hekmatpanah, 1990, 5-Hyddroxytryptamine uptake blockers altenuate the 5-hydroxytryptamine releasing effects of 3,4-methylenedioxymethamphetamine and releasing effects of 3,4-methylenedioxymethamphetamine and related agent., Eur J Pharmacol, 177, 95, 10.1016/0014-2999(90)90555-K Iravani, 2000, Direct effects of 3,4 methylenedioxymethamphetamine MDMA on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices., Synapse, 36, 275, 10.1002/(SICI)1098-2396(20000615)36:4<275::AID-SYN4>3.0.CO;2-# Schmidt, 1994, Blockjade of the striatal 5-HT2 receptors reduces the increase in extracellular concentrations of dopamine produced by anphetamine analogue MDMA., J Neurochem, 62, 1382, 10.1046/j.1471-4159.1994.62041382.x Johnson, 1991, Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems., Eur J Pharmacol, 193, 367, 10.1016/0014-2999(91)90153-H White, 1996, The effects of MDMA (Ecstasy) on monoaminergic neurotransmission in the central nervous system., Prog Neurobiol, 49, 455, 10.1016/0301-0082(96)00027-5 Gough, 1991, Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate., Pharmacol Biochem Behav, 39, 619, 10.1016/0091-3057(91)90137-Q Battaglia, 1988, Pharmacologic profile of MDMA (3-4-methylenedioxymethamphetamine) at various brain recognition sites., Eur J Pharmacol, 149, 159, 10.1016/0014-2999(88)90056-8 Battaglia, 1991, Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine) assessment using quantitative autoradiography., Synapse, 8, 249, 10.1002/syn.890080403 Commins, 1987, Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain., J Pharmacol Exp Ther, 241, 338 Reneman, 2002, The acute and chronic effects of MDMA (Ecstasy) on cortical 5-HT2A receptors in rat and human brain., Neuropsychopharmacology, 26, 387, 10.1016/S0893-133X(01)00366-9 Ricaurte, 1988, Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration., Brain Res, 446, 165, 10.1016/0006-8993(88)91309-1 Hatzidimitriou, 1999, Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously factors influencing abnormal recovery., J Neurosci, 19, 5096, 10.1523/JNEUROSCI.19-12-05096.1999 Fischer, 1995, Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug MDMA (ecstasy)., J Neurosci, 15, 5476, 10.1523/JNEUROSCI.15-08-05476.1995 Stone, 1988, Role of endogeneous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine., J Pharmacol Exp Ther, 247, 79 Hewitt, 1994, Chlormethizole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (ecstasy)., Neuropharmacology, 33, 1589, 10.1016/0028-3908(94)90134-1 Colado, 1999, Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) administration., Br J Pharmacology, 126, 911, 10.1038/sj.bjp.0702373 Schmidt, 1991, 5-HT2 Antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetmine by blocking the acute stimulation of dopamine synthesis reversal by L-Dopa., J Pharmacol Exp Ther, 256, 230 Sprague, 1995, The MAO-B inhibitor deprenyl protect against MDMA induced lipid peroxidation and long-term seotonergic deficits., J Pharmacol Exp Ther, 273, 375 Colado, 1993, 5-HT loss in rat brain following MDMA, p-chloroanphetamine and fenfluramine administration and effects of chlormetiazol and dizolcipine., Br J Pharmacol, 108, 583, 10.1111/j.1476-5381.1993.tb12846.x Liechti, 2000, Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram., Neuropsychopharmacology, 22, 513, 10.1016/S0893-133X(99)00148-7 McCreary, 1999, Pharmacological studies of the acute and chronic effects of (+)-3,4- methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B/1D receptors., J Pharmacol Exp Ther, 290, 965 Bankson, 2001, 3,4-methylenedioxy-methamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions., J Pharmacol Exp Ther, 297, 846 Navarro, 1999, Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in agonistic encounters between male mice., Prog Neuro-Psychopharmacol Biol Psychiatr, 23, 327, 10.1016/S0278-5846(98)00100-6 Glennon, 1984, Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents., Life Sci, 35, 2505, 10.1016/0024-3205(84)90436-3 Liechti, 2001, Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies., Hum Psychopharmacol Clin Exp, 16, 589, 10.1002/hup.348 Colado, 1997, In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine., Br J Pharmacol, 121, 889, 10.1038/sj.bjp.0701213 Colado, 1995, The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones., Eur J Pharmacol, 280, 343, 10.1016/0014-2999(95)00298-Y Steele, 1994, 3,4-methylenedioxymethamphetamine (MDMA) «ecstasy»: pharmacology and toxicology in animals and humans., Addiction, 89, 539, 10.1111/j.1360-0443.1994.tb03330.x Álamo C, López-Muñoz F. Aspectos neurofarmacológicos de la dependencia a opiáceos. En: Valbuena A, Álamo C, editores. Avances en toxicomanías y alcoholismo. Aspectos conceptuales, farmacológicos, clínico-terapéuticos y médico-legales. Alcalá de Henares: Servicio de Publicaciones de la Universidad de Alcalá, 1996; p. 39-56. Álamo C, López-Muñoz F, Cuenca E. Bases neurofarmacológicas para el abordaje terapéutico de la patología dual. En: Salvanés R, Álamo C, editores. Avances en patología dual. Aspectos diagnósticos, clínicos, terapéuticos y asistenciales. Alcalá de Henares: Servicio de Publicaciones de la Universidad de Alcalá, 1999; p. 163-90. Lin, 1977, Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation., Brain Res, 744, 351, 10.1016/S0006-8993(96)01210-3 White, 1994, MDMA depresses glutamate evoked neuroanl firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo., Neuroscience, 62, 41, 10.1016/0306-4522(94)90313-1 Kalivas, 1993, Neurotransmitter regulation of dopamine neurons in the ventral tegmental area., Brain Res Rev, 18, 75, 10.1016/0165-0173(93)90008-N Kelland, 1989, (±) 3,4-Methylenedioxymethamphetamine-induced changes in nigrostriatal dopamine neurons., Eur J Pharmacol, 169, 11, 10.1016/0014-2999(89)90812-1 Cameron, 1994, Cocaine inhibits GABA release in the VTA through endogenous 5-HT., J Neurosci, 14, 6763, 10.1523/JNEUROSCI.14-11-06763.1994 Cottler, 2001, Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria., Hum Psychopharmacol Clin Exp, 16, 599, 10.1002/hup.343 Parrott, 2001, Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research., Hum Psychopharmacol Clin Exp, 16, 557, 10.1002/hup.351 Gijsman, 1999, MDMA study: letter to the editor., Neuropsychopharmacology, 21, 597 Franken, 2001, Prevalence of MDMA (ecstasy) use and neurotoxicity., Eur Psychiatry, 16, 508, 10.1016/S0924-9338(01)00616-2 Cohen, 1995, Subjetive reports on the effects of the MDMA (Ecstasy) experience in humans., Prog Neuro-Psychopharmacol Biol Psychiatr, 19, 1137, 10.1016/0278-5846(95)00231-6 Parrott, 2002, Ecstasy/MDMA attributed problems reproted by novice, moderate and heavy recreational users., Hum Psychopharmacol Clin Exp, 17, 309, 10.1002/hup.415 Fox, 2002, Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (ecstasy) polydrug users., Psychopharmacology, 162, 203, 10.1007/s00213-002-1071-9 Parrott, 1997, Ecstasy (MDMA), anphetamine, and LSD: comparative mood profiles in recreational polydrug users., Hum Psychopharmacol, 12, 501, 10.1002/(SICI)1099-1077(199709/10)12:5<501::AID-HUP913>3.0.CO;2-V Peroutka, 1988, Subjetive effects of MDMA in recreational users., Neuropharmacology, 1, 273 Solowij, 1992, Recreational MDMA use in Sydney: A profile of Ecstasy users and their experiences with the drug., Br J Addiction, 92, 1161, 10.1111/j.1360-0443.1992.tb02003.x Curran, 1997, Mood and cognitive effects of MDMA (Ecstasy): Week-end high followed by mid week low., Addiction, 92, 821 Cami, 2000, Human pharmacology of 3,4-methylenedioxymethamphetamine (ecstasy): psychomotor performance and subjective effects., J Clin Psychopharmacol, 20, 455, 10.1097/00004714-200008000-00010 Camí, 1995 Davison, 1997, Ecstasy in recreational users: self-reported psychological and physiological effects., Hum Psychopharmacol Clin Exp, 12, 91, 10.1002/(SICI)1099-1077(199705/06)12:3<221::AID-HUP854>3.0.CO;2-C Stuerenburg, 2002, Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users., Neuroendocrinol Lett, 23, 259 Stephenson, 1999, The distribution of 3,4-methylenedioxymethamphetamine 'Ecstasy'-induced c-fos expression in rat brain., Neuroscience, 92, 1011, 10.1016/S0306-4522(99)00049-4 Reneman, 2000, Memory disturbances in «Ecstasy» users are correlated brain serotonin neurotransmission., Psychopharmacology, 148, 322, 10.1007/s002130050057 Bailly, 1999, Neuropsychiatric disorders induced by MDMA, Encephale, 25, 595 McGuire, 2000, Long term psychiatric and cognitive effects of MDMA use., Toxicol Lett, 112-113, 153, 10.1016/S0378-4274(99)00219-2 McCann, 1994, Brain serotonergic neurotoxicity after MDMA (ecstasy): a contolled study in humans., Neuropsychopharmacology, 10, 129, 10.1038/npp.1994.15 Price, 1989, Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users: preliminary observations., Arch Gen Psychiatry, 46, 20, 10.1001/archpsyc.1989.01810010022003 McCann, 1999, Altered neuroendocrine and behavioral responses to m-chlorophenylpipcrazine in 3,4-methylenedioxymethamphetamine (MDMA) users., Psychopharmacology, 147, 56, 10.1007/s002130051142 Gerra, 2000, Long-lasting effects of (+/-) 3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans., Biol Psychiatry, 47, 127, 10.1016/S0006-3223(99)00180-8 McCann`, 1998, Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings., Lancet, 352, 1433, 10.1016/S0140-6736(98)04329-3 Semple, 1999, Reduced in vivo binding to the serotonin trasnporter in the cerebral cortex of MDMA (ecstasy) users., Br J Psychiatry, 175, 63, 10.1192/bjp.175.1.63 Reneman, 2001, Investigating the potential neurotoxicity of ecstasy (MDMA): an imaging approach., Hum Psychopharmacol Clin Exp, 16, 579, 10.1002/hup.347 Reneman, 2000, MDMA (Ecstasy) and its association with cerebrovascular accidents: preliminari findings., AJNR Am J Neuroradiol, 21, 1001 Croft, 2001, Electrophysiological evidence of serotonergic impairment in long-term MDMA ecstasy users., Am J Psychiatry, 158, 1687, 10.1176/appi.ajp.158.10.1687 Obrocki, 1999, Ecstasy long-term effects on the human central nervous system revealed by positron emission tomography., Br J Psychiatry, 175, 186, 10.1192/bjp.175.2.186 McGuire, 1994, Diversity of psychopathology associated with use of 3,4 methylenedioxymethamphetamine., Br J Psychiatry, 165, 391, 10.1192/bjp.165.3.391 Soar, 2001, Psychiatric disorders in ecstasy (MDMA) users: a literature review focusingon personal predisposition and drug history., Hum Psychopharmacol Clin Exp, 16, 641, 10.1002/hup.350 Lieb, 2002, Mental disorders in ecstasy users: a prospective-longitudinal investigation., Drug Alcohol Depend, 68, 195, 10.1016/S0376-8716(02)00190-4 Dafters, 1999, Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence., Psychopharmacology, 145, 82, 10.1007/s002130051035 McCann, 1996, Adverse reactions with 3,4-methylendioxymethamphetamine (MDMA, Ecstasy)., Drug Safety, 115, 107, 10.2165/00002018-199615020-00003 Gamella, 1997 Screaton, 1992, Hyperpyrexia and rhabdomyolisis after MDM ecstasy abuse., Lancet, 339, 677, 10.1016/0140-6736(92)90834-P Stone, 1993, Treatment of ecstasy overdose with dantrolene, Anaesthesia, 48, 83, 10.1111/j.1365-2044.1993.tb06812.x Stein, 1999, Effects of ecstasy blocked by serotonin reuptake inhibitors., J Clin Psychiatry, 60, 485, 10.4088/JCP.v60n0711a 1997 Santo-Domingo, 2000 Del Río, 1999 1996, Editorial.Walkin on the moon., Lancet, 347, 207, 10.1016/S0140-6736(96)90395-5 Hegadoren, 1999, 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans., Neurosci Biobehav Rev, 23, 539, 10.1016/S0149-7634(98)00046-3 Demirkiran, 1996, Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome., Clin Neuropharmacol, 19, 157, 10.1097/00002826-199619020-00004